Podcasts about Commission

In this episode of the Real Estate Pros Podcast, host Michelle Kesil interviews Felix Mendelson, the founder of List Friendly LLC, a platform designed to streamline the process of hiring buyer agents and managing commission agreements. Felix discusses the inspiration behind List Friendly, the feedback received from users, and the unique features that set it apart from traditional real estate services. The conversation also covers the benefits for both buyers and sellers, as well as strategies for scaling the platform's reach.   Professional Real Estate Investors - How we can help you: Investor Fuel Mastermind:  Learn more about the Investor Fuel Mastermind, including 100% deal financing, massive discounts from vendors and sponsors you're already using, our world class community of over 150 members, and SO much more here: http://www.investorfuel.com/apply   Investor Machine Marketing Partnership:  Are you looking for consistent, high quality lead generation? Investor Machine is America's #1 lead generation service professional investors. Investor Machine provides true 'white glove' support to help you build the perfect marketing plan, then we'll execute it for you…talking and working together on an ongoing basis to help you hit YOUR goals! Learn more here: http://www.investormachine.com   Coaching with Mike Hambright:  Interested in 1 on 1 coaching with Mike Hambright? Mike coaches entrepreneurs looking to level up, build coaching or service based businesses (Mike runs multiple 7 and 8 figure a year businesses), building a coaching program and more. Learn more here: https://investorfuel.com/coachingwithmike   Attend a Vacation/Mastermind Retreat with Mike Hambright: Interested in joining a "mini-mastermind" with Mike and his private clients on an upcoming "Retreat", either at locations like Cabo San Lucas, Napa, Park City ski trip, Yellowstone, or even at Mike's East Texas "Big H Ranch"? Learn more here: http://www.investorfuel.com/retreat   Property Insurance: Join the largest and most investor friendly property insurance provider in 2 minutes. Free to join, and insure all your flips and rentals within minutes! There is NO easier insurance provider on the planet (turn insurance on or off in 1 minute without talking to anyone!), and there's no 15-30% agent mark up through this platform!  Register here: https://myinvestorinsurance.com/   New Real Estate Investors - How we can work together: Investor Fuel Club (Coaching and Deal Partner Community): Looking to kickstart your real estate investing career? Join our one of a kind Coaching Community, Investor Fuel Club, where you'll get trained by some of the best real estate investors in America, and partner with them on deals! You don't need $ for deals…we'll partner with you and hold your hand along the way! Learn More here: http://www.investorfuel.com/club   —--------------------

In the last episode on the Timeline, “Bacon's Aftermath 1: Diplomacy and Conspiracy 1677-1685,” we looked at the political and geopolitical aftermath of Bacon's Rebellion. This time we tackle the changes inside Virginia's society and economy in the years following Bacon's Rebellion, some of which may have been because of the Rebellion, and others of which probably would have happened anyway. The first half of the episode looks at the governorship of Thomas, Lord Culpeper, and his deft efforts to give effect to the Crown’s desire “to substitute the benevolent despotism of the king for the rapacious local despotism that had brought on one rebellion and threatened to bring on another.” In the second half, we consider the rise of Black slavery in Virginia and the decline of indentured servitude in the quarter century following Bacon’s Rebellion, the economic foundations of the shift, and the untended and somewhat surprising social consequence that by the early 18th century Virginia was a much more stable society than it had been when it had depended on English indentured servants. My Substack X – @TheHistoryOfTh2 – https://x.com/TheHistoryOfTh2 Facebook – https://www.facebook.com/HistoryOfTheAmericans Primary references for this episode (Commission earned for Amazon purchases through the episode notes on our website) Edmund S. Morgan, American Slavery, American Freedom John C. Coombs, “The Phases of Conversion: A New Chronology for the Rise of Slavery in Early Virginia,” The William and Mary Quarterly, July 2011. “An Act Concerning Servants and Slaves” (Virginia, 1705)

Send us a textIn this episode, Pastor Dom begins his teaching series on Fasting for 2026. 1 Thessalonians 5:2323 Now may the God of peace Himself sanctify you completely; and may your whole spirit, soul, and body be preserved blameless at the coming of our Lord Jesus Christ.Matthew 6:16-1816  “Moreover, when you fast, do not be like the hypocrites, with a sad countenance. For they disfigure their faces that they may appear to men to be fasting. Assuredly, I say to you, they have their reward. But you, when you fast, anoint your head and wash your face, 18  so that you do not appear to men to be fasting, but to your Father who is in the secret place; and your Father who sees in secret will reward you openly.Matthew 6:1515 But if you do not forgive men their trespasses, neither will your Father forgive your trespasses.Matthew 4:2-42 And when He had fasted forty days and forty nights, afterward He was hungry. 3  Now when the tempter came to Him, he said, “If You are the Son of God, command that these stones become bread.” 4  But He answered and said, “It is written, ‘Man shall not live by bread alone, but by every word that proceeds from the mouth of God.' ”Matthew 17:14-2114 And when they had come to the multitude, a man came to Him, kneeling down to Him and saying, 15 “Lord, have mercy on my son, for he is an epileptic and suffers severely; for he often falls into the fire and often into the water. 16  So I brought him to Your disciples, but they could not cure him.” 17 Then Jesus answered and said, “O faithless and perverse generation, how long shall I be with you? How long shall I bear with you? Bring him here to Me.” 18  And Jesus rebuked the demon, and it came out of him; and the child was cured from that very hour. 19 Then the disciples came to Jesus privately and said, “Why could we not cast it out?” 20 So Jesus said to them, “Because of your unbelief; for assuredly, I say to you, if you have faith as a mustard seed, you will say to this mountain, ‘Move from here to there,' and it will move; and nothing will be impossible for you. 21  However, this kind does not go out except by prayer and fasting.”Matthew 10:11 And when He had called His twelve disciples to Him, He gave them power over unclean spirits, to cast them out, and to heal all kinds of sickness and all kinds of disease.Luke 10:1717 Then the seventy returned with joy, saying, “Lord, even the demons are subject to us in Your name.”Hebrews 11:11 Now faith is the certainty of things hoped for, a proof of things not seen.James 2:1717 Thus also faith by itself, if it does not have works, is dead.Mark 9:23-2423  Jesus said to him, “If you can believe, all things are possible to him who believes.” 24  Immediately the father of the child cried out and said with tears, “Lord, I believe; help my unbelief!”Matthew 13:5858Now He did not do many mighty works there because of their unbelief.Matthew 8:1313 Then Jesus said to the centurion, “Go your way; and as you have believed, so let it be done for you.” And his servant was healed that same hour.Mark 11:22-2322 So Jesus answered and said to them, “Have faith in God. 23 For assuredly, I say to you, whoever says to this mountain, ‘Be removed and be cast into the sea,' and does not doubt in his heart, but believes that those things he says will be done, he will have whatever he says.

Welcome Online Family!  Join us in worshipping the King of Kings Jesus. If you have a need that we can pray for, please feel free to comment below or DM us and we would love pray with you! To support this ministry and help us continue to reach people all around the world click here: https://bit.ly/36vpxdD Subscribe to get notifications on all the latest sermons and worship covers, click on the bell icon to receive notifications every time we post! Share with your friends, colleagues, loved ones.  ------------------------------------------- Connect with us on all Commission Socials: https://linktr.ee/CommissionChurch

Fearless Agent Coach & Founder Bob Loeffler shares his insights on How to Handle Commission Objections and how it's making his Fearless Agent Coaching Students rich! Fearless Agent Coaching is the Highest Results Producing Real Estate Sales Training and Coaching Program in the Industry and we can prove it will work for you if it's a good fit! Call us today at 480-385-8810 to see if it may be  good fit for you! Telephone Prospecting for Realtors means Cold Calling, Door knocking, Calling for Sale By Owners, Calling Expired Listings, Calling your Sphere of Influence, Farming, Holding Open Houses, but Fearless Agent Coaching Students di all of these completely differently and get massively better results! Find out how! Listen in each week as Bob gives an overview and explains the big ideas behind making big money as a Fearless Agent! If you are earning less selling real estate than you wish you were, and you're open to the idea of having some help, We are here for you! You will never again be in a money making situation with a Buyer, Seller or Investor and not have the right words! You will be very confident! You will be a Fearless Agent! Call Bob anytime for more information about Fearless Agent Coaching for Agents, Fearless Agent Recruiting Training for Broker/Owners, or hiring Bob as a Speaker for your next Event! Call today 480-385-8810 - or go to https://fearlessagent.com Telephone Prospecting for Realtors means Cold Calling, Door knocking, Calling for Sale By Owners, Calling Expired Listings, Calling your Sphere of Influence, Farming, Holding Open Houses, Spin Selling, but Fearless Agent Coaching Students do all of these completely differently and get massively better results! Find out how! Are You an Owner of a Real Estate Company - need help Recruiting Producing Agents - Call today! 480-385-8810 and go to FearlessAgentRecruiting.com and watch our Recruiting Video Real Estate Coaching training Real estate training real estate coaching real estate speaker real estate coach real estate sales sales training realtor realtor training realtor coach realtor coaching realtor sales coaching realtor recruiting real estate agent real estate broker realtor prospecting real estate prospecting prospecting for listings calling expired listings calling for sale by owners realtor success Best Realtor Coach Best Real Estate Coach Spin SellingSupport the show: https://fearlessagent.comSee omnystudio.com/listener for privacy information.

Dallas' Landmark Commission is set to decide Monday whether a historic Oak Lawn church can keep its rainbow-painted front steps, a move made after Gov. Greg Abbott directed cities to remove rainbow crosswalks and other painted symbols from public streets. The church has urged neighbors and supporters to attend and speak at the 1 p.m. hearing at Dallas City Hall, saying the steps have become a marker of welcome and belonging. In other news, the CEO of Richardson-based Fossil Franco Fogliato knows what it takes to compete. The stock price recently hit its highest point since March of 2023 after sales declines narrowed and it got some good news on the debt front; with nearly 70 secondhand stores in the city, D-FW has become a thriving secondhand hub for big and small retailers; and the Dallas Cowboys season came to a close yesterday with an embarrassing 34-17 loss to the New York Giants. Learn more about your ad choices. Visit podcastchoices.com/adchoices

July 4, 2026, marks the 250th anniversary of the signing of the Declaration of Independence. In 2016, Congress established the America250 Commission to plan events to celebrate the semiquincetennial. America250 Commission Chair Rosie Rios joins us to talk about several of these events which will occur over the next year, including the U.S. Army's 250th anniversary parade that took place on June 14, 2025, and other initiatives that the public can participate in leading up to the anniversary. She also talks about serving as the 43rd Treasurer of the United States (2009-2016). Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a textIn this episode, Pastor Dom teaches us what Christmas is all about. Luke 2:1-201 In those days Caesar Augustus issued a decree that a census should be taken of the entire Roman world. 2 (This was the first census that took place while[a] Quirinius was governor of Syria.) 3 And everyone went to their own town to register.4 So Joseph also went up from the town of Nazareth in Galilee to Judea, to Bethlehem the town of David, because he belonged to the house and line of David. 5 He went there to register with Mary, who was pledged to be married to him and was expecting a child. 6 While they were there, the time came for the baby to be born, 7 and she gave birth to her firstborn, a son. She wrapped him in cloths and placed him in a manger, because there was no guest room available for them. 8 And there were shepherds living out in the fields nearby, keeping watch over their flocks at night. 9 An angel of the Lord appeared to them, and the glory of the Lord shone around them, and they were terrified. 10 But the angel said to them, “Do not be afraid. I bring you good news that will cause great joy for all the people. 11 Today in the town of David a Savior has been born to you; he is the Messiah, the Lord. 12 This will be a sign to you: You will find a baby wrapped in cloths and lying in a manger.” 13 Suddenly a great company of the heavenly host appeared with the angel, praising God and saying, 14 “Glory to God in the highest heaven, and on earth peace to those on whom his favor rests.” 15 When the angels had left them and gone into heaven, the shepherds said to one another, “Let's go to Bethlehem and see this thing that has happened, which the Lord has told us about.” 16 So they hurried off and found Mary and Joseph, and the baby, who was lying in the manger. 17 When they had seen him, they spread the word concerning what had been told them about this child, 18 and all who heard it were amazed at what the shepherds said to them. 19 But Mary treasured up all these things and pondered them in her heart. 20 The shepherds returned, glorifying and praising God for all the things they had heard and seen, which were just as they had been told.Matthew 1:2323 “Behold, the virgin shall be with child, and bear a Son, and they shall call His name Immanuel,” which is translated, “God with us.”John 10:1010“ … I have come that they may have life, and that they may have it more abundantly.”I Corinthians 15:33 “…that Christ died for our sins according to the Scriptures,”John 3:1616““For this is how God loved the world: He gave his one and only Son, so that everyone who believes in him will not perish but have eternal life.”John 3:1717 “God sent his Son into the world not to judge the world, but to save the world through him.”Romans 10:9-109 that if you confess with your mouth Jesus as Lord, and believe in your heart that God raised Him from the dead, you will be saved; 10 for with the heart a person believes, resulting in righteousness, and with the mouth he confesses, resulting in salvation.Psalm 119:105105 Your word is a lamp to my feet And a light to my path.John 8:1212 …“I am the light of the world.Matthew 5:1414 “You are the light of the world…

Abandoned uranium mine waste has been a big deal for decades, but almost no one had an inkling about what we should do to solve the problem. The scale of the challenge is huge, with various estimates ranging between 1 and 8 billion tons of uranium mining waste rock spread over more than 10,000 sites, nearly all of which are in western states and Native American sovereign nations. The Navajo Nation is the jurisdiction with the biggest burden – a substantial portion of the waste is on Navajo lands and spread over 500 or more sites. Some have dismissed or minimized the problem by pointing to the relatively low material concentrations and the low radiation doses emitted. But low concentrations multiplied by tens of millions of tons and thousands of sites calculates to distressingly large numbers. It’s also important to remember that the contaminating minerals of concern are heavy metals that might be lightly radioactive, but they also have a level of chemical toxicity that also causes negative health impacts on humans and animals. Though billions of dollars have been allocated for cleaning up the waste piles, there hasn’t been much progress because the available solution set has been limited to on-site burial in engineered landfills or moving the material “somewhere else.” The landfill option doesn’t remove the potential threat to groundwater and the barriers are designed to last about 100 years. The vast majority of the contaminating minerals will still be there after the designed barriers have deteriorated. There has been little or no success in finding suitable or agreeable places to take the waste and even if there were, the mass of material means that most of the available clean up funds would be consumed in transportation. Not surprisingly, there has not been a shortage of large established contracting companies willing to be paid tens of millions of dollars to study the issue and move some dirt around. Enter John Lee and Greyson Buckingham, a pair of innovative entrepreneurs. They recognized the scale of the problem and the importance of effective solutions. They developed a patented technology called High Pressure Slurry Ablation that separates the contaminating minerals – mostly uranium and radium 226 – from sand and rock and concentrates those minerals into about 20% of the mass of the input stream. The clean fraction can meet stringent NRC unrestricted release criteria while the fraction containing the minerals will have a high enough concentration to turn a pile of contaminated material into valuable ore. John Lee, with deep experience and education in mining and materials processing, developed the initial idea for HPSA. Greyson Buckingham added his legal training, business acumen and political experience. They formed a company called Disa Technologies in 2018 and patiently began the process of refining their ideas into useful and reliable machinery. Additionally, they entered into a plodding process of obtaining permission to deploy their problem-solving technology in an environmentally beneficial and cost effective manner. Starting with a state regulatory engagement in 2018, Disa Technologies was recently – September 30, 2025 – awarded a service provider’s license from the Nuclear Regulatory Commission. That license comes with a significant, but reasonably achievable condition to demonstrate HPSA on a commercial scale before entering into wide deployment of multiple units. Though it took about half a decade of staff engagement and Commission decision-making to determine the proper licensing framework, the NRC was able to review Disa’s service provider license application in six months (March–September 2025). During the regulatory engagement process, Disa Technologies developed strong alliances with political representatives from affected states, with leaders among the Native American nations and with communities that have been seeking solutions to the waste issue for decades. They also produced solid scientific evidence of the efficacy of their inventions and demonstrated it to the satisfaction of the Environmental Protection Agency and the Nuclear Regulatory Commission. The saga is fascinating. For Atomic Show #339, I spoke with Greyson Buckingham about his company, its technology, the importance of cleaning up abandoned uranium mine (AUM) waste, the utility of HPSA in processing other critical mineral ores, the sometimes frustrating interactions with the NRC during period from 2020-2024 and the refreshingly competent and mission-oriented NRC that has been evolving during the past year. Neither I nor Nucleation Capital, the sponsor of the Atomic Show and Atomic Insights, have any financial interest in Disa as of January 5, 2025, the date that this post and the associated audio recording are released.

"Bloody Crowns and Broken Myths: Michael Livingston on the Real Hundred Years War" The Not Old Better Show, Smithsonian Associates Interview Series For more details, check out Smithsonian Associates:  https://smithsonianassociates.org/ticketing/programs/hundred-years-war The Hundred Years War: A New History Bloody Crowns A New History of the Hundred Years War ⚔️ Henry V at Agincourt. Joan of Arc at Orléans. But that's just the beginning… Smithsonian Associate, Military historian Michael Livingston joins The Not Old Better Show to expose what really happened during the Hundred Years War—and why it wasn't 100 years at all. Think two centuries of shifting alliances, brutal innovation, and the making of modern Europe.

#737 What if your next big business move came from discovering a product no one else has seen? In this episode hosted by Kirsten Tyrrel, we're joined by longtime entrepreneur Paul Baron, founder of The Wall Printer. At 73 years old, Paul shares the lessons learned across decades of business ownership — starting in sales and evolving into launching innovative foreign products in the U.S. market. You'll hear how he built a company that sells large-format vertical printing machines while empowering others to start their own businesses, why he's never forgotten a lesson from his first boss, and how he turned the chaos of COVID into a surprising advantage. If you're curious about licensing, partnerships, or launching a product most people have never seen before — this episode is packed with golden insights! (Original Air Date - 5/18/25) What we discuss with Paul: + From sales rep to equity owner + Launching foreign products in the U.S. + Lessons from a 73-year entrepreneurial journey + Building The Wall Printer business model + COVID pivot that drove long-term growth + Why relationships drive business success + Commission vs. ownership mindset + Creating revenue share for employees + Using LinkedIn for business discovery + How to identify products with potential Thank you, Paul! Check out The Wall Printer at ⁠TheWallPrinter.com⁠. Follow Paul on ⁠LinkedIn⁠ or his other ⁠social channels⁠. Watch the ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠video podcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ of this episode! To get access to our FREE Business Training course go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠MillionaireUniversity.com/training⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ To get exclusive offers mentioned in this episode and to support the show, visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠millionaireuniversity.com/sponsors⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Learn more about your ad choices. Visit megaphone.fm/adchoices

To show compassion is to suffer with another person. You can't show compassion from far away; you have to get close, offering patience, service, and love to the suffering. In Matthew 9:35-38, Jesus demonstrates compassion and invites His followers to live compassionately, too. Where will you practice compassion this week? MESSAGE NOTES: https://www.bible.com/events/49545344 RESOURCES: https://www.canyonridge.org BLOG: https://canyonridge.org/blogs/

Pastor Jon Purkey delivered a sobering and powerful word in “As A Man Thinketh,” reminding us that the battle for our lives doesn't begin in our actions, it begins in our minds.Unchecked thoughts spiral, grow, and quietly shape the direction of our lives. Without anchoring ourselves in God's Word, we wander the wilderness, searching for peace in places it was never meant to be found.You don't need new information, you need TRANSFORMATION. When we meditate on God's Word daily, our thoughts change, our desires align, and our lives begin to reflect His perfect plan as we continue our journey from Cross to Commission.“AS A MAN THINKETH” is now streaming.WATCH | YouTube, Nexus AppLISTEN | Spotify, Apple Podcasts, Amazon Music

X: @KeithJKrach @250Freedom_ @ileaderssummit @americasrt1776 @NatashaSrdoc @JoelAnandUSA @supertalk @JTitMVirginia Join America's Roundtable (https://americasrt.com/) radio co-hosts Natasha Srdoc and Joel Anand Samy with Keith J. Krach, CEO of Freedom 250, which was launched by President Donald J. Trump. Freedom 250 is the national, non-partisan organization leading the celebration of our Nation's 250th birthday. Working together with the White House Task Force 250, federal agencies, and the Commission, Freedom 250 serves as the official public-private partnership that connects, aligns, and amplifies national and local efforts to deliver the defining presidential moments of this anniversary year. At its heart, Freedom 250 is creating a movement of citizens, organizations, companies, and leaders from across the country to honor our Nation's proud history, cherish our God-given freedoms, and build the Golden Age of Opportunity for the next 250 years. Keith Krach is the Former Under Secretary of State, technology entrepreneur, and Chairman of the Krach Institute for Tech Diplomacy at Purdue University. A Silicon Valley innovator and dedicated public servant, he founded and led several category-creating companies—including Ariba, the world's largest B2B e-commerce network, which transacts $3.7 trillion annually; and DocuSign, inventors of digital transaction management, serving over a billion users. Visit: Freedom250.org americasrt.com (https://americasrt.com/) https://ileaderssummit.org/ | https://jerusalemleaderssummit.com/ America's Roundtable on Apple Podcasts: https://podcasts.apple.com/us/podcast/americas-roundtable/id1518878472 X: @KeithJKrach @250Freedom_ @ileaderssummit @americasrt1776 @NatashaSrdoc @JoelAnandUSA @supertalk @JTitMVirginia America's Roundtable is co-hosted by Natasha Srdoc and Joel Anand Samy, co-founders of International Leaders Summit and the Jerusalem Leaders Summit. America's Roundtable (https://americasrt.com/) radio program focuses on America's economy, healthcare reform, rule of law, security and trade, and its strategic partnership with rule of law nations around the world. The radio program features high-ranking US administration officials, cabinet members, members of Congress, state government officials, distinguished diplomats, business and media leaders and influential thinkers from around the world. Tune into America's Roundtable Radio program from Washington, DC via live streaming on Saturday mornings via 68 radio stations at 7:30 A.M. (ET) on Lanser Broadcasting Corporation covering the Michigan and the Midwest market, and at 7:30 A.M. (CT) on SuperTalk Mississippi — SuperTalk.FM reaching listeners in every county within the State of Mississippi, and neighboring states in the South including Alabama, Arkansas, Louisiana and Tennessee. Tune into WTON in Central Virginia on Sunday mornings at 9:30 A.M. (ET). Listen to America's Roundtable on digital platforms including Apple Podcasts, Spotify, Amazon, Google and other key online platforms. Listen live, Saturdays at 7:30 A.M. (CT) on SuperTalk | https://www.supertalk.fm

Send us a textGabe and Jana discuss the following cases:2025 OK 61, 579 P.3d 591, 09/30/2025, BARFELL v. FREEMAN HEALTH SYSTEM AND GULSHAN UPPAL, M.D., et al.2025 OK 62, 579 P.3d 602, 09/30/2025, BJORKMAN, ET AL. v. NOBLE2025 OK 63, 578 P.3d 1209, 09/30/2025, PYBAS v. THE HONORABLE JEFF CRITES2025 OK 65, 579 P.3d 622, 10/07/2025, BEVERLY THOMPSON, Next Friend of CHARLENE HUGHES, an Individual v. HEARTWAY CORPORATION2025 OK 68, 579 P.3d 636, 10/07/2025, WHITE AND WADDELL v. STITT2025 OK 72, 578 P.3d 162, 10/14/2025, ESTATE OF CUNNINGHAM, CHERYL MOORE and OK CITY COMM. FOUNDATION. v. MCCLENDON2025 OK 73, 578 P.3d 154, 10/14/2025, AMERICA'S CAR MART v. THE HONORABLE DAMON CANTRELL2025 OK 78, 579 P.3d 723, 10/28/2025, LAKE REGION ELECTRIC, et al. v. STATE, ex rel. OKLAHOMA CORP. COMMISSION, et al.

Le Grand reportage week-end de ce samedi est consacré à l'Afrique du Sud puis à la France. 30 ans après la création par Nelson Mandela de la fameuse Commission Vérité et Réconciliation, une innovation en matière de justice pour essayer de panser les plaies de l'apartheid, mais des suspects de crimes n'ont toujours pas été inquiétés... En seconde partie, nous revenons sur la situation dans les campagnes françaises où là où les médecins manquent. (Rediffusion) 30 ans plus tard, l'ombre des crimes de l'apartheid continue de planer sur l'Afrique Le 19 juillet 1995 était signée, par Nelson Mandela, la loi qui créait la Commission vérité et réconciliation. Une expérience de justice restaurative pour tenter de panser les terribles plaies de l'apartheid. Une dynamique qui a créé des émules partout dans le monde. Mais aujourd'hui, le bilan est finalement assez mitigé, car les suspects qui n'ont pas obtenu d'amnistie n'ont jamais été inquiétés par les tribunaux. Le temps n'efface pas tout et désormais, les familles des victimes veulent des réponses.  Un Grand reportage de Claire Bargelès et Vincent Hugues qui s'entretiennent avec Jacques Allix. Alerte aux soins en zones rurales La désertification médicale touche 85% du territoire français, 9 millions de personnes sont concernées. Selon le ministère de la Santé, cela devrait s'aggraver. En Lozère, département le moins peuplé de France, il n'y a qu'une maternité, et qu'un seul centre d'urgence, à l'hôpital de Mende. Les pompiers mettent en moyenne 25 minutes pour toucher au but, contre 14 minutes à l'échelle nationale. Une proposition de loi, la loi Garot chemine entre les assemblées pour essayer d'amener les professionnels de santé à tenter l'aventure. Un Grand reportage de Justine Rodier qui s'entretient avec Jacques Allix.

durée : 01:00:00 - Les Nuits de France Culture - par : Albane Penaranda, Mathias Le Gargasson, Antoine Dhulster - Par Raphaël Krafft - Avec Catherine de Wenden (membre de la Commission nationale de déontologie de la sécurité) - Réalisation Jean-Philippe Navarre - réalisation : Rafik Zénine, Vincent Abouchar, Emily Vallat

"We proposed a concept to the American Society of Clinical Oncology (ASCO), recognizing that extravasation management requires significant interdisciplinary collaboration and rapid action. There can occasionally be uncertainty or lack of clear guidance when an extravasation event occurs, and our objective was to look at this evidence with the expert panel to create a resource to support oncology teams overall. We hope that the guideline can help mitigate harm and improve patient outcomes," Caroline Clark, MSN, APRN, AGCNS-BC, OCN®, EBP-C, director of guidelines and quality at ONS, told Chelsea Backler, MSN, APRN, AGCNS-BC, AOCNS®, VA-BC, oncology clinical specialist at ONS, during a conversation about the ONS/ASCO Guideline on the Management of Antineoplastic Extravasation. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 2, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the management of antineoplastic extravasation. Episode Notes  Complete this evaluation for free NCPD. ONS/ASCO Guideline on the Management of Antineoplastic Extravasation ONS Podcast™ episodes: Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 335: Ultrasound-Guided IV Placement in the Oncology Setting Episode 145: Administer Taxane Chemotherapies With Confidence Episode 127: Reduce and Manage Extravasations When Administering Cancer Treatments ONS Voice articles: Access Devices and Central Lines: New Evidence and Innovations Are Changing Practice, but Individual Patient Needs Always Come First New Extravasation Guidelines Provide Recommendations for Protecting Patients and Standardizing Care Standardizing Venous Access Assessment and Validating Safe Chemo Administration Drastically Lowers Rates of Adverse Venous Events This Organization's Program Trains Non-Oncology Nurses to Deliver Antineoplastic Agents Safely ONS books: Access Device Guidelines: Recommendations for Nursing Practice and Education (fourth edition) Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) ONS courses: Complications of Vascular Access Devices (VAD) and IV Therapy ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ ONS Oncology Treatment Modalities Clinical Journal of Oncology Nursing articles: Chemotherapy Extravasation: Incidence of and Factors Associated With Events in a Community Cancer Center Standardized Venous Access Assessment and Safe Chemotherapy Administration to Reduce Adverse Venous Events Oncology Nursing Forum article: Management of Extravasation of Antineoplastic Agents in Patients Undergoing Treatment for Cancer: A Systematic Review ONS huddle cards: Antineoplastic Administration Chemotherapy Immunotherapy Implanted Venous Port ONS position statements: Administration (Infusion and Injection) of Antineoplastic Therapies in the Home Education of the Nurse Who Administers and Cares for the Individual Receiving Antineoplastic Therapies ONS Guidelines™ for Extravasation Management ONS Oncologic Emergencies Learning Library ONS/ASCO Algorithm on the Management of Antineoplastic Extravasation of Vesicant or Irritant With Vesicant Properties in Adults American Society of Clinical Oncology (ASCO) Podcast: Management of Antineoplastic Extravasation: ONS-ASCO Guideline To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "The focus of this guideline was specifically on intravenous antineoplastic extravasation or when a vesicant or an irritant with vesicant properties leaks out of the vascular space. This can cause an injury to the patient that's influenced by several factors including the specific drug that was involved in the extravasation, whether it was DNA binding, how much extravasated, the affected area, and individual patient characteristics." TS 1:48 "The panel identified and ranked outcomes that mattered most with extravasation. Not surprising, one of the first was tissue necrosis. Like, 'How are we going to prevent tissue necrosis and preserve tissue?' The next were pain, quality of life, delays in cancer treatment: How is an extravasation going to delay cancer treatment that's vital to the patient? Is an extravasation also going to result in hospitalization or additional surgical interventions that would be burdensome to the patient? ... We had a systematic review team that then went in and summarized the data, and the panel applied the grading of recommendations, assessment, development, and evaluation (GRADE) criteria, grading quality of evidence and weighing factors like patient preferences, cost, and feasibility of an intervention. From there, they developed their recommendations." TS 7:35 "The panel, from the onset, wanted to make sure we had something visual for our readers to reference. They combined evidence from the systematic review, other scholarly sources, and their real-world clinical experience to make this one-page supplementary algorithm. They wanted it to be comprehensive and easy to follow, and they included not only those acute management steps but also guidance on 'How do I document this and what are the objective and subjective assessment factors to look at? What am I going to tell the patient?' In practice, for use of that, I would compare it to your current processes and identify any gaps to inform policies in your individual organizations." TS 16:34 "The guidelines don't take place of clinician expertise; they're not intended to cover every situation, but a situation that keeps coming up that we should talk about as a limitation, is we're seeing these case reports of tissue injury with antibody–drug conjugate extravasation. There's still not enough evidence to inform care around the use of antidotes with those agents, so this still needs to be addressed on a case-by-case basis. We still need publication of those case studies, what was done, and outcomes to help inform direction." TS 19:24 "Beyond the acute management is to ensure thorough documentation regarding extravasation. Whether you're on electronic documentation or on paper, are the prompts there for the nurse to capture all of the factors that should be captured regarding that extravasation? The size, the measurement, the patient's complaints. Is there redness? Things like that. And then within the teams, everyone should know where to find that initial extravasation assessment so that later on, if they're in a different clinic, they have something to go by to see how the extravasation is healing or progressing. ... I think there's an importance here, too, to our novice oncology nurses and their preceptors. This could be anxiety-provoking for the whole team and the patient, so we want to increase confidence in management. So, I think using these resources for onboarding novice oncology nurses is important." TS 22:34

Ed Hartin, MS, EFO, FIFireE, CFO retired as fire chief with East County Fire and Rescue in Camas, Washington after an over 50-year fire service career serving with urban, suburban and rural fire and rescue agencies on the east and west coasts. Ed has international training and consulting practice since 2006 and has delivered fire dynamics and command training in Europe, Asia, South America, North America, and Australasia. He is co-author of 3D Firefighting and has authored numerous articles for fire service trade publications in the United States and Europe. Ed has undergraduate degrees in fire protection technology and fire service administration and a master's degree in postsecondary, adult, and continuing education. He holds the Chief Fire Officer designation from the Commission on Professional Credentialing and is a Fellow of the Institution of Fire Engineers and is a past-president of the USA Branch. Ed served as a member on several Underwriter Laboratories (UL FSRI) technical panels and as a UL FSRI Advisory Board for 11 years and now serves as an Emeritus member of the board. Since 2017, Ed has also developed over 500 tactical decision games to provide ICs with deliberate practice to build competence.Thank you to our fantastic sponsors: Elkhart Brass, Key Hose, and Vanguard Safety Wear.

2026 - Bliain Úr faoi Mhaise DaoibhseA very happy New Year to all readers of this column, to the staff of the Belfast Media Group and The Irish Echo. And to you good readers who have stayed with me over the years.None of us know what 2026 will bring but we can be sure it will be interesting. May it also be good to you all and to your families. Beirigí bua. Eyes On The Prize. 2025 was a good year for Irish Unity. All of those advocating for a new Ireland, including Sinn Féin's Commission on the Future of Ireland, worked hard and effectively promoting the message that Irish Unity will be good for the people of the island of Ireland. Crucially, both houses of the Oireachtas, the Dáil and the Seanad, passed motions calling on the Irish government to begin the process of planning and preparing for Unity referendums. These include The Oireachtas Good Friday Agreement Committee. This is the only all-Ireland committee in Leinster House. It is unique in that Members of Parliament from the north join TDs and Senators to work on issues relating to the implementation of the Good Friday Agreement.The Good Friday Agreement remains the basis for relations on the island of Ireland and between the islands of Ireland and Britain. However, its implementation has been challenged, principally by indifference from London and a lack of consistent and positive leadership from Dublin.‘I'm so scared, please come'For as long as I have been a republican activist I have been reading and writing about the impact of British colonialism on peoples around the world. As the largest empire in human history Britain's conquests and exploitation of other places resulted in untold misery, death and hardship for those living under British rule - not least here in Ireland. To maintain its domination, the British Empire used violence and dehumanised the peoples it sought to exploit. Behind its claim of being a guardian of the ‘rule of law' Britain stole land and property, exploited mineral resources and reduced native peoples to little more than slaves.Among those many locations was Palestine. British policy is largely responsible for the decades of war that have plighted that land for a hundred years. Current British government policy is facilitating the genocide of the Palestinian people by the Israeli apartheid regime.I have visited Palestine and Israel on at least four occasions, including the Gaza Strip in 2009. I walked along the ‘separation wall' – a monstrous perversion designed to imprison Palestinians into smaller and smaller ghettoes.

On New Year's Eve, America250 Commission Chair Rosie Rios talks about the special celebrations tonight related to the U.S.'s 250th birthday in 2026, New York City & New Orleans are among the cities increasing their New Year's Eve security and world leaders issue New Year's messages; House Republicans schedule a hearing looking at Minnesota social welfare programs fraud, inviting both Republican state lawmakers and Gov. Tim Walz (D-MN) to testify; number of Jeffrey Epstein-related files the Justice Department is working through to release now reportedly tops 5 million; New York City mayor-elect Zohran Mamdani (D) names a new schools chancellor a day before he takes office; former Sen. Ben Nighthorse Campbell (D-CO) has died. We  hear his 2004 remarks at the dedication for the Smithsonian Institution's National Museum of the American Indian. Learn more about your ad choices. Visit megaphone.fm/adchoices

Stephan Stern, PhD, DABT, Director of Research and Development, Nanotechnology Characterization Lab (NCL), Frederick National Laboratory for Cancer Research, Maryland, USA; and Ruben Boado, PhD, Professor of Medicine, University of California at Los Angeles, California, USA, discuss the use of nanotechnology in the treatment of lysosomal disorders.This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees.To obtain CME/CE credit, visit https://checkrare.com/learning/p-grids2025-session2-nanotechnology-and-lysosomal-disorders/Learning ObjectivesDescribe recent advances in the use of nanotechnology to treat lysosomal disordersDescribe the role of nanotechnology in addressing unmet needs in lysosomal disordersFacultyStephan Stern, PhD, DABTDirector of Research and Development, Nanotechnology Characterization Lab (NCL), Frederick National Laboratory for Cancer ResearchRuben Boado, PhDProfessor of Medicine, University of California at Los AngelesDisclosuresAffinityCE staff, LDRTC staff, planners, and reviewers, have no relevant financial relationships with ineligible companies to disclose. Faculty disclosures, listed below, will also be disclosed at the beginning of the Program.Stephan Stern, PhD, DABTDr. Stern has no relevant financial relationships to disclose. Ruben Boado, PhDDr. Boado has no relevant financial relationships to disclose.Mitigation of Relevant Financial RelationshipsAffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.Accreditation and Credit DesignationPhysiciansThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician AssistantsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.NursesAffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of 1 hours of continuing nursing education credit.Nurse PractitionersAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.Genetic CounselorsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.Other ProfessionalsAll other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity. Participation CostsThere is no cost to participate in this activity.CME InquiriesFor all CME policy-related inquiries, please contact us at ce@affinityced.comSend customer support requests to cds_support+ldrtc@affinityced.com

Behzad Najafian, MD, Professor, Department of Laboratory Medicine & Pathology, Department of Medicine at the University of Washington, Washington, USA discusses the use of artificial intelligence in identifying and managing lysosomal disorders.This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees.To obtain CME/CE credit, visit https://checkrare.com/learning/p-grids2025-session1-ai-in-medicine-transforming-the-landscape-of-tissue-based-diagnostics/Learning ObjectivesDescribe recent advances in the applications of AI in lysosomal disorder diagnosis and its clinical relevanceFacultyBehzad Najafian, MD Professor, Department of Laboratory Medicine & Pathology, Department of Medicine, University of WashingtonDisclosuresAffinityCE staff, LDRTC staff, planners, and reviewers, have no relevant financial relationships with ineligible companies to disclose. Faculty disclosures, listed below, will also be disclosed at the beginning of the Program.Behzad Najafian, MDDr. Najafian is on the Advisory Board/Consultant for Sanofi, Amicus, Avrobio, 4DMT,Sangamo, Freeline, AceLink, Relay, CRISPR, ELOXX, SPARK, UNIQURE. He receives grants/research support from Amicus. Mitigation of Relevant Financial RelationshipsAffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.Accreditation and Credit DesignationPhysiciansThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician AssistantsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.NursesAffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of 1 hours of continuing nursing education credit.Nurse PractitionersAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.Genetic CounselorsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.Other ProfessionalsAll other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity. Participation CostsThere is no cost to participate in this activity.CME InquiriesFor all CME policy-related inquiries, please contact us at ce@affinityced.comSend customer support requests to cds_support+ldrtc@affinityced.com

Mia Horowitz, PhD, Tel Aviv University; Aitor Aguirre, PhD, Michigan State University, Michigan, USA; and Ying Sun, PhD, University of Cincinnati, discuss the use of organoid models in lysosomal disorder research and drug development.This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees.To obtain CME/CE credit, visit https://checkrare.com/learning/p-grids2025-session3-organoids-and-lab-grown-models-in-lysosomal-disorders/Learning ObjectivesDescribe the use of heart organoid models to better understand the pathophysiology of lysosomal disorders and its clinical relevanceDescribe the use and application of brain organoid models in neuropathic Gaucher disease research and treatmentFacultyMia Horowitz, PhD, Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University.Aitor Aguirre, PhD, Associate Professor of Biomedical Engineering, Institute for Quantitative Health Science and Engineering, Chief, Division of Developmental and Stem Cell Biology (IQ), Director, MSU Stem Cell Core, Michigan State University.Ying Sun, PhD, Professor, Cincinnati Children's Hospital Medical Center, University of Cincinnati.DisclosuresAffinityCE staff, LDRTC staff, planners, and reviewers, have no relevant financial relationships with ineligible companies to disclose. Faculty disclosures, listed below, will also be disclosed at the beginning of the Program.Mia Horowitz, PhDDr. Horowitz has no relevant financial relationships to disclose.Aitor Aguirre, PhDDr. Aguirre has no relevant financial relationships to disclose.Ying Sun, PhDDr. Sun receives research support from Enkefalos Biosciences and Yuhan Corporation.Mitigation of Relevant Financial RelationshipsAffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.Accreditation and Credit DesignationPhysiciansThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician AssistantsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.NursesAffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of 1 hours of continuing nursing education credit.Nurse PractitionersAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.Genetic CounselorsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.Other ProfessionalsAll other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity. Participation CostsThere is no cost to participate in this activity.CME InquiriesFor all CME policy-related inquiries, please contact us at ce@affinityced.comSend customer support requests to cds_support+ldrtc@affinityced.com

Oral Alpan, MD, Immunologist, Amerimmune, Virginia, USA; Svenja Keller, PhD student, University of Zurich, Switzerland; Shoshana Revel-Vilk, MD, PhD, Director, Gaucher Unit & Pediatric Hematology/Oncology Unit, Shaare Zedek Medical Center, Jerusalem, Israel; Patrick Deegan, MD, Consultant Metabolic Physician, University of Cambridge, UK; and Ravi Kamath, MD, PhD, Head of Musculoskeletal Radiology, Inova Health System, Virginia, USA, discuss the applications of AI in the diagnosis and treatment of lysosomal disorders.This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees.To obtain CME/CE credit, visit https://checkrare.com/learning/p-grids2025-session4-expanded-applications-of-ai-in-lysosomal-disorders/Learning ObjectivesDescribe how emerging AI and machine learning technologies are advancing disease modeling and biomarker development.Describe how emerging AI and machine learning technologies are advancing therapeutic target identification across lysosomal disorders.FacultyOral Alpan, MD, Immunologist, AmerimmuneSvenja Keller, PhD student, University of ZurichShoshana Revel-Vilk, MD, PhD, Director, Gaucher Unit & Pediatric Hematology/Oncology Unit, Shaare Zedek Medical CenterPatrick Deegan, MD, Consultant Metabolic Physician, University of CambridgeRavi Kamath, MD, PhD, Head of Musculoskeletal Radiology, Inova Health SystemDisclosuresAffinityCE staff, LDRTC staff, planners, and reviewers, have no relevant financial relationships with ineligible companies to disclose. Faculty disclosures, listed below, will also be disclosed at the beginning of the Program.Oral Alpan, MD Dr. Alpan has no relevant financial relationships to disclose.Svenja KellerMs. Keller has no relevant financial relationships to disclose.Shoshana Revel-Vilk, MD, PhDDr. Revel-Vilk receives grant/research support from Sanofi and Takeda. She is a member of the Speakers Bureau for Sanofi and Takeda, and a member of the Advisory Board for Takeda.Patrick Deegan, MDDr. Deegan is a consultant and advisory board member with Sanofi, Takeda, and Amicus.He also receives research support from Sanofi and Amicus.Ravi Kamath, MD, PhDDr. Kamath is on an advisory board for Intrinsic Therapeutics. He is also a consultant forSanofi, Takeda, and Spur Therapeutics.Mitigation of Relevant Financial RelationshipsAffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.Accreditation and Credit DesignationPhysiciansThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician AssistantsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.NursesAffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of 1 hours of continuing nursing education credit.Nurse PractitionersAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.Genetic CounselorsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.Other ProfessionalsAll other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity. Participation CostsThere is no cost to participate in this activity.CME InquiriesFor all CME policy-related inquiries, please contact us at ce@affinityced.comSend customer support requests to cds_support+ldrtc@affinityced.com

Duarte C. Barral, PhD, Associate Professor, NOVA Medical School, NOVA University of Lisbon, Portugal; Nuno Raimundo, PhD, Associate Professor, Department of Cellular and Molecular Physiology; Penn State College of Medicine, Pennsylvania, USA; Betul Celik, PhD, Postdoctoral Fellow, Nemours Children's Health, Delaware, USA; and Gregory Newby, PhD, Assistant Professor, Department of Genetic Medicine, Johns Hopkins School of Medicine, Maryland, USA,discuss the principles of theranostics and its application in lysosomal disorders.This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees.To obtain CME/CE credit, please visit https://checkrare.com/learning/p-grids2025-session5-theranostics-and-lysosomal-disorders/ Learning ObjectivesDescribe lysosomal and inter-organelle mechanisms that contribute to pathology in lysosomal disorders, and how these pathways are being leveraged for diagnostic and therapeutic applications.Describe current and emerging theranostic strategies for lysosomal disorders.FacultyDuarte C. Barral, PhD, Associate Professor, NOVA Medical School, NOVA University of Lisbon, Nuno Raimundo, PhD, Associate Professor, Department of Cellular and Molecular Physiology; Penn State College of MedicineBetul Celik, PhD, Postdoctoral Fellow, Nemours Children's HealthGregory Newby, PhD, Assistant Professor, Department of Genetic Medicine, Johns Hopkins School of MedicineDisclosuresAffinityCE staff, LDRTC staff, planners, and reviewers, have no relevant financial relationships with ineligible companies to disclose. Faculty disclosures, listed below, will also be disclosed at the beginning of the Program.Duarte C. Barral, PhD Dr. Barral's group receives grant support from Sea4Us.Nuno Raimundo, PhDDr. Raimundo has no relevant financial relationships to disclose.Betul Celik, PhDDr. Celik has no relevant financial relationships to disclose.Gregory Newby, PhDDr. Newby has no relevant financial relationships to disclose.Mitigation of Relevant Financial RelationshipsAffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.Accreditation and Credit DesignationPhysiciansThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician AssistantsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.NursesAffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of 1 hours of continuing nursing education credit.Nurse PractitionersAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.Genetic CounselorsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.Other ProfessionalsAll other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity. Participation CostsThere is no cost to participate in this activity.CME InquiriesFor all CME policy-related inquiries, please contact us at ce@affinityced.comSend customer support requests to cds_support+ldrtc@affinityced.com

Shunji Tomatsu, MD, PhD, Professor and Head, Nemours Children's Health, Delaware, USA; Alessandra d'Azzo, PhD, Emerita Faculty, Genetics, St. Jude Children's Research Hospital, Tennessee, USA; Merve Emecen Sanli, MD, Associate Professor, Department of Pediatrics, University of Texas Southwestern Medical Center, Texas, USA; and Ryan Colburn, patient with Pompe disease and president of Odimm Inc, discuss new and emerging gene therapies for lysosomal disorders.This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees.To obtain CME/CE credit, please visit https://checkrare.com/learning/p-grids2025-session6-current-issues-in-gene-therapies-for-lysosomal-disorders/  Learning ObjectivesDescribe current and emerging gene therapy data in lysosomal disorders and its clinical relevanceDescribe role of patients in gene therapy developmentFacultyShunji Tomatsu, MD, PhD, Professor and Head, Nemours Children's HealthAlessandra d'Azzo, PhD, Emerita Faculty, Genetics, St. Jude Children's Research HospitalMerve Emecen Sanli, MD, Associate Professor, Department of Pediatrics, University of Texas Southwestern Medical CenterRyan Colburn. Odimm, Inc.DisclosuresAffinityCE staff, LDRTC staff, planners, and reviewers, have no relevant financial relationships with ineligible companies to disclose. Faculty disclosures, listed below, will also be disclosed at the beginning of the Program.Shunji Tomatsu, MD, PhD Dr. Tomatsu has received the following grants: Morquio Foundations and families: Scarlett Grifith, Bennett, A Cure for Roberts, and Morquio Conference; MPS Societies: Japanese, National, and Austrian; NIH grants: 1-R01-HD102545, NIH, NICHD, Tomatsu (PI), 1R01HD104814-01A1, NIH, NICHD, Langan, T.J. (PI), Role: Site-PI, R43HD114328-01, NIH, ACOSTA, WALTER (PI), Role: site PI, 1R43AR084638-01, NIH, MOUNZIH, KHALID (PI); Foundation of NIH: FNIH RFP NUMBER: 2022-BGTC-005 Tomatsu (PI). Alessandra d'Azzo, PhDDr. D'Azzo has no relevant financial relationships to disclose.Merve Emecen Sanli, MDDr. Sanli has no relevant financial relationships to disclose.Ryan ColburnMr. Colburn has an advisory, consulting and/or project based relationship or stock holding with: Abeona Therapeutics, Amicus Therapeutics, Astellas Gene Therapies, Avidity Biosciences, Bayer, Catalyst Pharmaceuticals, Denali Therapeutics, M6P Therapeutics, Sangamo Therapeutics, Sanofi, Solid Biosciences.Mitigation of Relevant Financial RelationshipsAffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.Accreditation and Credit DesignationPhysiciansThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician AssistantsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.NursesAffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of 1 hours of continuing nursing education credit.Nurse PractitionersAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.Genetic CounselorsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.Other ProfessionalsAll other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity. Participation CostsThere is no cost to participate in this activity.CME InquiriesFor all CME policy-related inquiries, please contact us at ce@affinityced.comSend customer support requests to cds_support+ldrtc@affinityced.com

Mi-décembre 2025, la Commission européenne a proposé de revenir sur l'interdiction de vente de véhicules neufs à moteur thermique après 2035. [Cette émission est une rediffusion de nos programmes] Pour simplifier les procédures et alléger les normes, différents amendements au pacte vert ont déjà été adoptés suite à un vote conjoint des députés du Parti Populaire Européen et de ceux des groupes d'extrême-droite.  À lire aussiUE: qu'est-ce que le Pacte Vert, enjeu des élections européennes?   En Albanie, la Vjosa et son parc national sont à nouveau menacés Les énergies fossiles et les activités industrielles accélèrent le réchauffement du climat, et détruisent aussi directement de nombreux écosystèmes, là où la réglementation est peu contraignante, ou peu appliquée. Il y a deux ans, le gouvernement albanais inaugurait le premier Parc National de rivière sauvage en Europe. Une victoire pour les écologistes qui luttaient depuis plus de 10 ans pour protéger la Vjosa, un fleuve à la biodiversité exceptionnelle. Mais deux ans et demi plus tard, la survie de cet espace naturel est à nouveau menacée, comme l'a constaté Louis Seiller sur les bords du fleuve, dans le sud de l'Albanie.  Le lac Balaton, en Hongrie, est lui aussi en danger Les Hongrois le surnomment la « mer du peuple », c'est le plus grand lac d'Europe, et un lieu de tourisme balnéaire très prisé. Mais son niveau d'eau est désormais très bas, car il subit de plein fouet les effets du changement du climat - des effets visibles à l'œil nu. Les précisions de Florence Labruyère. La chronique musique de Vincent Théval : Prince of Assyria Mach Cha Zamara  Voyage au pays du «çay» Avec une consommation d'environ  quatre kilos par personne et par an... C'est en Turquie, pays aux confluents de l'Europe et de l'Asie, que l'on boit le plus de thé au monde. Même si les Turcs ont adopté cette boisson assez récemment, elle est devenue incontournable dans leur vie sociale, mais aussi commerciale, politique... Partout, à toute occasion, dans les maisons, les magasins, les cafés, on boit du thé noir du matin au soir. À tel point que la production locale – pourtant au cinquième rang mondial – suffit tout juste à satisfaire les besoins du pays. À Ankara, Anne Andlauer. À lire aussiL'Union européenne renonce au tout-électrique en 2035 et autorise une part limitée de voitures thermiques

Mi-décembre 2025, la Commission européenne a proposé de revenir sur l'interdiction de vente de véhicules neufs à moteur thermique après 2035. [Cette émission est une rediffusion de nos programmes] Pour simplifier les procédures et alléger les normes, différents amendements au pacte vert ont déjà été adoptés suite à un vote conjoint des députés du Parti Populaire Européen et de ceux des groupes d'extrême-droite.  À lire aussiUE: qu'est-ce que le Pacte Vert, enjeu des élections européennes?   En Albanie, la Vjosa et son parc national sont à nouveau menacés Les énergies fossiles et les activités industrielles accélèrent le réchauffement du climat, et détruisent aussi directement de nombreux écosystèmes, là où la réglementation est peu contraignante, ou peu appliquée. Il y a deux ans, le gouvernement albanais inaugurait le premier Parc National de rivière sauvage en Europe. Une victoire pour les écologistes qui luttaient depuis plus de 10 ans pour protéger la Vjosa, un fleuve à la biodiversité exceptionnelle. Mais deux ans et demi plus tard, la survie de cet espace naturel est à nouveau menacée, comme l'a constaté Louis Seiller sur les bords du fleuve, dans le sud de l'Albanie.  Le lac Balaton, en Hongrie, est lui aussi en danger Les Hongrois le surnomment la « mer du peuple », c'est le plus grand lac d'Europe, et un lieu de tourisme balnéaire très prisé. Mais son niveau d'eau est désormais très bas, car il subit de plein fouet les effets du changement du climat - des effets visibles à l'œil nu. Les précisions de Florence Labruyère. La chronique musique de Vincent Théval : Prince of Assyria Mach Cha Zamara  Voyage au pays du «çay» Avec une consommation d'environ  quatre kilos par personne et par an... C'est en Turquie, pays aux confluents de l'Europe et de l'Asie, que l'on boit le plus de thé au monde. Même si les Turcs ont adopté cette boisson assez récemment, elle est devenue incontournable dans leur vie sociale, mais aussi commerciale, politique... Partout, à toute occasion, dans les maisons, les magasins, les cafés, on boit du thé noir du matin au soir. À tel point que la production locale – pourtant au cinquième rang mondial – suffit tout juste à satisfaire les besoins du pays. À Ankara, Anne Andlauer. À lire aussiL'Union européenne renonce au tout-électrique en 2035 et autorise une part limitée de voitures thermiques

Here's a question that keeps salespeople up at night: How do you ask for more compensation when you're getting competitive external job offers without sounding like you're issuing an ultimatum? That's the question posed by Brady from Arkansas. Brady's been getting legitimate job offers from recruiters, and he's wondering how to leverage these opportunities into better compensation at his current company without burning bridges or coming across as disloyal. If you've ever found yourself in this position, you know it's a delicate dance. You want to be paid what you're worth, but you also don't want to destroy the relationships and goodwill you've built. So how do you navigate this conversation? The Right Way to Have the Conversation If you're getting external job offers from legitimate companies with strong brands, the key is in how you frame the conversation with your boss. Here's the approach: "I really like working here, and I want to stay at this company. I love it. But I've got another company out there that's a good company. They're a great brand, they're well known, and they're making this job offer to me at a significantly higher level of compensation. It's hard for me to say no to that. I feel like I need to bring this to you before I make a decision because I like working here." Notice what you're NOT saying. You're not walking in with an ultimatum saying, "If you don't give me this, I'm leaving." Instead, you're saying, "I want to stay here. I like it here. I'm just in a situation where they're offering me enough that it's turning my head and I'm looking their way." This approach keeps the door open for a productive conversation about what might be possible without threatening your current employer or damaging your relationship. When Loyalty Actually Matters Now, before you go schedule that meeting with your boss, you need to ask yourself a hard question: Do you owe this company some loyalty? If you were down on your luck, lost a job, and they came along and gave you something that saved you, you probably owe them some loyalty for that. Not forever, but there's a little bit of honor in not just jumping to the next place immediately. You also need to think about your resume. If you've just got there and a year later you're jumping to another place, that's on your resume. And believe it or not, even in today's world, that still means something. I won't hire people who jump from job to job every year. I don't care how good they are because they're probably going to jump again. So think long term: Am I demonstrating to a future employer that I'm worth investing more money in? The answer is yes when you gave them three years of your life, performed at a really high level, and now you're going to leverage that to go level up elsewhere. Speaking Your Boss's Language Here's what most salespeople get wrong when asking for more money: They forget to speak the language their boss understands. If you walk into your sales leader's office and say, "I want to make more money," you know what they're going to tell you? "Go sell more." And they're right. If you've got a great compensation plan with no limit on how much commission you can make, the answer is simple: crank out more sales. So before you ask for more base salary, ask yourself: Do I have a limit on how much commission I can make? If the answer is no, then your first conversation should be about getting bigger opportunities. Try this approach: "I can sell. I'm hitting numbers, but I'm not making the money I want. What can you do to give me bigger accounts, bigger opportunities, bigger customers? Give me better leads. What can you do to get me in a situation where I can earn more?" This is speaking the boss's language. You're showing that you want to produce more, not just get paid more for the same work. If you get shut down in that situation, then you have another conversation. The Commission vs. Base Salary Play If you're a baller and you've proven you can sell, here's a move most salespeople never consider when negotiating compensation: Ask for a higher commission percentage instead of a higher base salary. I honestly don't care about base. I think a base matters when you're getting started, and it's nice to have, but I would much rather have a higher commission percentage than a higher base. Here's how you position it: "In the open market, I can take a similar job and make $400,000. I want to make the same thing here. Now there's two ways we could do this. One is that you can increase my base salary. Two is you give me a higher commission rate, and I think the commission rate should be this. I think I'm worth that." What you're basically saying is that your cost of sales is going to be variable. They only pay you if you sell it, so their carrying costs stay the same. In my company, the people who don't take a base salary make more than double in commission what people who do take a base salary bring home. There's a massive difference because the people saying "pay me more commission" are saying "I'm willing to put skin in the game in order to make more." Now, this doesn't work if you're at a massive company with a thousand salespeople and rigid HR policies. But if you work for a smaller organization where people can make decisions, have an honest conversation around this approach. You might even propose a tiered structure: "You can pay me your base commission on everything up to the quota you gave me. But once I cross that quota, I want my commission to roll up so that if I get over this number, the rate scales." That's a conversation most entrepreneurial leaders will entertain because it's putting your money where your mouth is. What Money Can't Buy Here's the thing most people miss when they're chasing the next big paycheck: There's always money out there you can chase. You have an obligation to yourself and your family to make as much as you possibly can in sales. But there's also the value of working in a place that values you. There's more than just the money. There's the freedom, the flexibility, and the opportunity to be part of something that gives you purpose. I had somebody come to me recently and ask this question, and I said, "This job that you're moving to that's going to pay you all this money, suddenly you're going to have someone who's micromanaging and telling you what to do every single day. In your current role, you're not making as much money, but you call the shots on your day every single day. Nobody even messes with you. Are you willing to sign up for that?" They said their wife told them the exact same thing. Maybe that's a sign that having the freedom and flexibility is more valuable than making a lot of money but being miserable because everything you do is being micromanaged. The Bottom Line When it's time to ask for more money, remember these principles: Bring the conversation to your boss before making a decision. Frame it as wanting to stay, not threatening to leave. Consider what you owe in loyalty. If they gave you a chance when you needed one, factor that into your decision. Speak your boss's language. Ask for bigger opportunities before asking for more base pay. Consider the commission play. If you're confident in your abilities, asking for higher commission rates can be more lucrative than base salary increases when looking at total compensation. Weigh the intangibles. Money isn't everything if you're trading freedom and fulfillment for a micromanaged existence. The best compensation conversations happen when you approach them with confidence, gratitude, and a clear understanding of your value. That's how you get paid what you're worth without burning bridges along the way. Want to learn more about leveraging your personal brand to create more career opportunities? Check out Jeb's newest book, The LinkedIn Edge, and discover how to turn your LinkedIn profile into a powerful career and sales tool.

In this episode of The China Desk, host Steve Yates speaks with US-China Economic and Security Review Commission members Randy Schriver and Mike Kuiken about the Commission's latest annual report to Congress. The conversation breaks down China's rapid advances in space as a warfighting domain, quantum computing and encryption threats, biotechnology competition, and deep vulnerabilities in U.S. supply chains. Drawing on decades of national security experience, the guests explain why technological literacy, allied coordination, and long-term investment are now critical to maintaining U.S. and allied security in the Indo-Pacific. Watch Full-Length Interviews: https://www.youtube.com/@ChinaDeskFNW

With the new season just a month away and the new year ringing in this week, Jake, Safe, and Ryan turn their attention to 2026 with a New Year's Resolution for some teams, some 2026 lacrosse predictions, and a look back at some of our favorite things in 2025.The 2026 season's fast approaching, so subscribe to The Crosse Commission on YouTube to get yourself ready for our exclusive live streams coming up around the bend! 

EDITORIAL: Independent People's Commission: Right idea, wrong execution | Dec. 31, 2025Subscribe to The Manila Times Channel - https://tmt.ph/YTSubscribeVisit our website at [https://www.manilatimes.net](https://www.manilatimes.net/)Follow us:Facebook - https://tmt.ph/facebookInstagram - https://tmt.ph/instagramTwitter - https://tmt.ph/twitterDailyMotion - https://tmt.ph/dailymotionSubscribe to our Digital Edition - https://tmt.ph/digitalCheck out our Podcasts:Spotify - https://tmt.ph/spotifyApple Podcasts - https://tmt.ph/applepodcastsAmazon Music - https://tmt.ph/amazonmusicDeezer: https://tmt.ph/deezerStitcher: https://tmt.ph/stitcherTune In: https://tmt.ph/tunein#TheManilaTimes#VoiceOfTheTimes Hosted on Acast. See acast.com/privacy for more information.

C'est le dernier épisode d'un long feuilleton juridico-commercial vieux de plus d'une décennie. Le Parlement européen a adopté de justesse, le 26 novembre, un nouvel accord commercial sur la pêche et l'agriculture entre l'UE et le Maroc. Après l'annulation du précédent texte datant de 2019, les indépendantistes du Front Polisario demandaient que les produits issus du Sahara occidental en soient exclus, mais ce ne sera finalement pas le cas. De notre correspondant à Casablanca, La nouvelle version de l'accord agricole Rabat-Bruxelles comprend bien les produits du Sahara occidental. Des tomates, essentiellement, et des melons qui poussent, hors sol, sous d'immenses serres. Ils continueront de bénéficier d'une réduction des droits de douane. « Au final, le Maroc demeure le principal bénéficiaire puisqu'il obtient une reconnaissance pratique de la continuité des préférences accordées à ses exportations, y compris celles provenant des provinces du Sud », détaille Zaher Badr Al Azrak, professeur de droit des affaires à l'université Hassan II de Casablanca. « Provinces du Sud », c'est l'expression utilisée au Maroc pour désigner ces territoires revendiqués par le Front Polisario. Le nouveau texte amendé par la Commission européenne propose une formulation juridique inédite, pour respecter l'arrêt de la Cour de justice de l'UE. « Le changement ne porte pas sur la substance même de l'accord commercial, mais plutôt sur sa mise en œuvre. Les Européens ont introduit des mécanismes pratiques et techniques », poursuit-il. Une concurrence déloyale ? À l'exigence de traçabilité de la Cour, Bruxelles répond par un étiquetage spécifique, mentionnant simplement les deux régions de production autour des villes de Dakhla et de Laâyoune. Le Front Polisario dénonce une disposition illégale. « En fait, il n'y a pas eu de grands changements. L'Union européenne et le Maroc ont repris pratiquement les mêmes dispositions. Ils les ont reconduites dans ce traité. Je pense que le Maroc a enregistré une victoire par rapport à ses détracteurs », souligne l'analyste économique et politique marocain, Driss Aïssaoui. Les échanges agricoles ne cessent de progresser entre le Maroc et l'UE. L'année dernière, ils ont atteint plus de 7 milliards d'euros. Ainsi, tout en annulant l'accord commercial en 2024, la Cour de justice de l'UE l'avait maintenu pour une durée transitoire de 12 mois. « L'Union européenne est un partenaire fort et indispensable, mais qui fonctionne selon des équilibres internes complexes, analyse Zaher Badr Al Azrak. C'est précisément pour cela que la diversification des partenariats en Afrique, en Asie ou en Amérique latine n'est plus une option secondaire, mais une nécessité stratégique pour le royaume. » Le texte tout juste adopté compte encore des ennemis : des syndicats agricoles français et espagnols qui dénoncent une concurrence déloyale. Le Front Polisario aussi, qui prévoit de saisir à nouveau la Cour de justice de l'Union européenne d'ici la fin du mois de décembre. À lire aussiLes produits du Sahara occidental inclus dans l'accord commercial Maroc-UE

Le 19 juillet 1995 était signée, par Nelson Mandela, la loi qui créait la Commission vérité et réconciliation. Une expérience de justice restaurative pour tenter de panser les terribles plaies de l'apartheid. Une dynamique qui a créé des émules partout dans le monde. Mais aujourd'hui, le bilan est finalement assez mitigé, car les suspects qui n'ont pas obtenu d'amnistie n'ont jamais été inquiétés par les tribunaux. Le temps n'efface pas tout et désormais, les familles des victimes veulent des réponses.  « 30 ans plus tard, l'ombre des crimes de l'apartheid continue de planer sur l'Afrique du Sud », un Grand reportage signé Claire Bargelès et Valentin Hugues. [Rediffusion du 8 septembre 2025]

Welcome Online Family!  Join us in worshipping the King of Kings Jesus. If you have a need that we can pray for, please feel free to comment below or DM us and we would love pray with you! To support this ministry and help us continue to reach people all around the world click here: https://bit.ly/36vpxdD Subscribe to get notifications on all the latest sermons and worship covers, click on the bell icon to receive notifications every time we post! Share with your friends, colleagues, loved ones.  ------------------------------------------- Connect with us on all Commission Socials: https://linktr.ee/CommissionChurch

Welcome Online Family!  Join us in worshipping the King of Kings Jesus. If you have a need that we can pray for, please feel free to comment below or DM us and we would love pray with you! To support this ministry and help us continue to reach people all around the world click here: https://bit.ly/36vpxdD Subscribe to get notifications on all the latest sermons and worship covers, click on the bell icon to receive notifications every time we post! Share with your friends, colleagues, loved ones.  ------------------------------------------- Connect with us on all Commission Socials: https://linktr.ee/CommissionChurch

Low Co-operating Commission in Real Estate | How to Handle It as a Buyer's Agent

Welcome to The Daily, where we study the Bible verse by verse, chapter by chapter, every day. Read more about Project23 and partner with us as we teach every verse of the Bible on video. Our text today is Judges 19:1-3. This isn't just another story—it's a wake-up call. The Levite's failure reminds us how quickly spiritual leaders can drift from conviction to compromise. God is looking for men and women who will not only know His Word but live it, defend it, and pass it on with courage. In those days, when there was no king in Israel, a certain Levite was sojourning in the remote parts of the hill country of Ephraim, who took to himself a concubine from Bethlehem in Judah. And his concubine was unfaithful to him, and she went away from him to her father's house at Bethlehem in Judah, and was there some four months. Then her husband arose and went after her, to speak kindly to her and bring her back. He had with him his servant and a couple of donkeys. And she brought him into her father's house. And when the girl's father saw him, he came with joy to meet him. — Judges 19:1-3 By the time we reach Judges 19, Israel has plunged to its lowest point. Even the Levites—men once set apart to teach and guard God's law—no longer remember it. The opening line says it all: "There was no king in Israel." In other words, there was no authority, no truth, no standard—only self-rule. Here stands a Levite, a man supposed to model holiness. Instead, he takes a concubine—a live-in girlfriend with marital benefits but no covenant commitment. She betrays him, runs home, and after months apart, he decides he wants her back. The relationship is dysfunctional from every direction. But the greater tragedy is this: a priest who should lead God's people can't even lead himself. That's the climate of moral collapse—when spiritual leaders trade holiness for cultural conventions, then the nation no longer knows what righteousness looks like. We live in the same era of moral relativism—everyone doing what seems right in their own eyes. Churches ordain what God calls sin. Pulpits preach self-esteem instead of repentance. Pastors chase applause over truth. But notice they still wear the robes, carry the titles, build buildings, and quote a few verses—but like this Levite, they've abandoned the covenant. And the result? Confused believers. Compromised faith. A generation that can no longer tell the difference between God's truth and cultural tolerance. We've come a long way from Joshua's bold declaration—"As for me and my house, we will serve the Lord." Now we say, "As for me and the truth, we'll do what feels right." When leaders forget the Word, the people follow their feelings. And when that happens, nations collapse from the inside long before enemies ever invade. The Levite's story isn't just a scandal—it's a warning shot and a challenge. When God's people drift from His Word, it's not enough to simply shake our heads—we must act. Step up where he stepped back. Lead where he lacked courage. Recommit to Scripture in your home, your marriage, your circle of influence. Because when we return to God's Word, broken relationships can be healed, leadership restored, and love redeemed. ASK THIS: Where have you seen "moral relativism" creep into the church? Have you traded biblical truth for cultural comfort in any area of life? What voices in your life hold you accountable to Scripture? How can you encourage your pastor—or yourself—to stand firm on truth this week? DO THIS: Pray daily for pastors and leaders to preach truth with courage and clarity. Recommit to reading Scripture before social media or news; make God's Word your authority again. PRAY THIS: Lord, reignite conviction in Your people. Make us builders of truth and defenders of faith. Give us courage to lead boldly where others have drifted, and help us restore what weak leadership has lost. Commission us to act—not just believe—so that Your Word defines every choice we make. Amen. PLAY THIS: "Come to the Altar."

Caribbean CIPs should tighten vetting “pending discontinuation of those schemes,” reads a recent report by the EU Commission. View the full article here.Subscribe to the IMI Daily newsletter here. 

"They [monoclonal antibodies] are able to cause tumor cell death by binding to and blocking to necessary growth factor signaling pathways for tumor cell survival. That's going to be dependent on the target of the antibody, but I'll give an example of epidermal growth factor, or EGFR. This is overexpressed in several different kinds of cancers where activation of this growth factor increases the amount of proliferation and migration of cancer cells. So, if we bind to it and block to it, then that would help halt these pathways and stop cancer cell growth," Carissa Ganihong, PharmD, BCOP, oncology and bone marrow transplantation clinical pharmacist at Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about monoclonal antibodies. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) (including 45 minutes of pharmacotherapeutic content) by listening to the full recording and completing an evaluation at courses.ons.org by December 26, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge in the history of, the mechanism of action of, and the use of monoclonal antibodies in the treatment of cancer.  Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 383: Pharmacology 101: Bispecific Antibodies Episode 375: Pharmacology 101: VEGF Inhibitors Episode 338: High-Volume Subcutaneous Injections: The Oncology Nurse's Role Episode 283: Desensitization Strategies to Reintroduce Treatment After an Infusion-Related Reaction Episode 275: Bispecific Monoclonal Antibodies in Hematologic Cancers and Solid Tumors ONS Voice articles: An Oncology Nursing Overview of Biosimilars Make Subcutaneous Administration More Comfortable for Your Patients Oncology Nurses' Role in Translating Biomarker Testing Results Reduce Chair Time by as Much as 16 Minutes by Priming IVs With Drug Shorter Administration Times Still Require High-Acuity Care The Names of Targeted Therapies Give Clues to How They Work ONS Voice drug reference sheets: Datopotamab deruxtecan-dlnk Enfortumab vedotin Margetuximab-cmkb Mirvetuximab soravtansine-gynx Nivolumab and hyaluronidase-nvhy Nivolumab and relatlimab-rmbw Pembrolizumab and berahyaluronidase alfa-pmph Retifanlimab-dlwr ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) ONS course: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ Clinical Journal of Oncology Nursing articles: Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial Management of Immunotherapy Infusion Reactions Nurse-Led Grading of Antineoplastic Infusion-Related Reactions: A Call to Action Safety and Adverse Event Management of VEGFR-TKIs in Patients With Metastatic Renal Cell Carcinoma Oncology Nursing Forum articles: Administration of Subcutaneous Monoclonal Antibodies in Patients With Cancer Depressive Symptoms and Quality of Life Associated With the Use of Monoclonal Antibodies in Breast Cancer Treatment ONS huddle cards: Bispecifics Checkpoint Inhibitors Monoclonal Antibodies Other ONS resources: Biomarker Database Bispecific Antibodies video Patient Education Sheets Antibodies article: A Comprehensive Review About the Use of Monoclonal Antibodies in Cancer Therapy Cureus article:  A Comprehensive Review of Monoclonal Antibodies in Modern Medicine: Tracing the Evolution of a Revolutionary Therapeutic Approach Association of Cancer Care Centers (ACCC) homepage Cancer Immunology, Immunotherapy article: Therapeutic Antibodies in Oncology: An Immunopharmacological Overview Drugs@FDA package inserts Future Oncology article: Biosimilars: What the Oncologist Should Know Hematology/Oncology Pharmacy Association homepage National Comprehensive Cancer Network homepage Network for Collaborative Oncology Development and Advancement (NCODA) subcutaneous therapy article Oncolink: Side Effects of Immunotherapy World Health Organization: New International Nonproprietary Names (INN) Monoclonal Antibody Nomenclature Scheme To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Prior to monoclonal antibodies, all we really had were these toxic chemotherapies or toxic radiation, so it was recognized how great it would be if we could have a treatment that was much more specific to the tumor cells and have agents that have less toxicities. These advancements in monoclonal antibody production began in the 1980s. ... Eventually, we had the first monoclonal antibody that was approved by the U.S. Food and Drug Administration (FDA) for an oncologic indication, rituximab." TS 4:14  "Nowadays, we do have treatments that are also considered tumor-agnostic. This is when a patient has a certain biomarker, then that treatment can be given and FDA approval was given, regardless what type of tumor the patient has. We typically see these kinds of tumor-agnostic therapies more so in patients who have recurrent or advanced diseases in solid tumors. One monoclonal antibody example that comes to mind is dostarlimab. That's a checkpoint inhibitor that's approved for patients who are deficient in mismatch repair mechanism." TS 23:48 "Our immune system constantly has this surveillance system and it's able to recognize foreign pathogens, abnormal cells, and even precancerous cells. And they're able to eliminate them before they become cancerous. But on the flip side, one of the regulatory mechanisms that we have so our immune system doesn't attack itself is the presence of checkpoints. When these checkpoints bind to their ligands, this can then act as an off switch so that, again, our immune system is not going to attack itself. But then the tumor cells can take advantage of this and actually use this mechanism to evade the immune system. So, when we're giving a checkpoint inhibitor, now we're removing that off switch. As a consequence, common adverse effects can include things like immune mediated adverse events. These most commonly affect the skin, gastrointestinal tract, and liver. Essentially, this can cause any '-itis' you can think of." TS 26:36 "Looking at strategies to prevent infusion reactions, one example is the use of premedication. If premedication is recommended, this typically includes any combination of antipyretics, which is typically acetaminophen. Antihistamine, which is typically an H1 antagonist like diphenhydramine. Although, there could be cases where we want to substitute this agent because maybe the patient has been tolerating therapy okay, and they're having a lot of side effects. So, we might use a second-generation antihistamine in some cases. The premedication may be given with or without some kind of steroid, whether that's methylprednisolone, hydrocortisone, or dexamethasone." TS 29:53 "We tend to think of monoclonal antibody usage to be primary oncology, but that's not really the case. The first monoclonal antibodies that were developed were not for oncologic indications, they were for transplant indication for cardiac indication. So, they're really diversely utilized across all specialties and medicines. We have monoclonal antibodies for hyperlipidemia, for neurology, for rheumatology, so the uses are so very expansive across all specialties." TS 41:01

L'année 2025 restera comme une année charnière pour l'économie mondiale, marquée par le retour tonitruant de Donald Trump à la Maison-Blanche et ses décisions commerciales radicales. Cette émission spéciale d'Éco d'ici, éco d'ailleurs revisite, avec les experts qui sont intervenus à notre micro, les moments clés d'une année économique tumultueuse, entre guerres commerciales, crises géopolitiques, révolution de l'intelligence artificielle et urgence climatique.  

durée : 00:24:26 - L'invité de 8h20 - Le député LFI de Seine-Saint-Denis, Éric Coquerel, également président de la Commission des finances, est l'invité de France Inter. Il explique pourquoi son groupe ne votera pas le budget. Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

Retired FBI agent Michael Clarke and retired DEA agent Jack McFarland review their 2004 joint FBI and DEA investigation of "The Commission," a violent criminal gang operating in the U.S. Virgin Islands which includes St. Thomas, St. John, and St. Croix, whose members were convicted in federal court for racketeering, murder, and drug trafficking. The case was conducted under the Organized Crime Drug Enforcement Task Force (OCDETF) program, the Safe Streets Task Force initiative, and the High Intensity Drug Trafficking Area (HIDTA) program. Mike and Jack both served as agents for 32 years.    Check out episode show notes, photos, and related articles: https://jerriwilliams.com/382-michael-clarke-and-jack-mcfarland-disrupting-the-commission-us-virgin-islands/     Join my Reader Team to get the FBI Reading Resource - Books about the FBI, written by FBI agents, the 20 clichés about the FBI Reality Checklist, and keep up to date on the FBI in books, TV, and movies via my monthly email. Join here. http://eepurl.com/dzCCmL  Buy me a coffee - https://www.buymeacoffee.com/JerriWilliams   Check out my FBI books, non-fiction and crime fiction, available as audiobooks, ebooks and paperbacks wherever books are sold. https://jerriwilliams.com/books/

Les journalistes et experts de RFI répondent également à vos questions sur l'expulsion de Kényans en Afrique du Sud, une photo de Donald Trump supprimée des dossiers de l'affaire Epstein et l'alliance Iran/Venezuela contre les États-Unis. Mercosur-UE : l'impossible signature ?  Alors que près de 7 300 agriculteurs européens ont manifesté leur colère contre l'accord UE-Mercosur, la présidente de la Commission européenne, Ursula von der Leyen, a annoncé un report de la signature de l'accord. Pourquoi la France est-elle autant opposée à cet accord commercial ? Une signature est-elle possible sans Paris ? Avec Stéphane Geneste, journaliste au service économie de RFI, présente la chronique « Aujourd'hui l'économie ».      Afrique du Sud : pourquoi l'expulsion de sept Kényans irrite Washington ?  L'Afrique du Sud a expulsé sept ressortissants kényans accusés de travailler illégalement pour un programme américain de relocalisation des Afrikaners. Comment les Américains justifient-ils la présence de ces Kényans sur le territoire sud-africain ? Cela fait plusieurs mois que Washington accuse Pretoria de persécuter les Afrikaners. Sur quels éléments reposent ces accusations ? Avec Liza Fabbian, journaliste au service Afrique de RFI.      Affaire Epstein : Trump à nouveau au cœur des interrogations   La récente publication des archives judiciaires de l'affaire Jeffrey Epstein aux États-Unis a été marquée par la mystérieuse disparition du fichier n°468 et d'une quinzaine d'autres documents, dont une photo associant le président Donald Trump à Epstein. Pourquoi cette photo a-t-elle été effacée ? Le département de justice pourrait-il être influencé par Donald Trump ? Avec Jérôme Viala-Gaudefroy, docteur en civilisation américaine, spécialiste en rhétorique présidentielle.       Iran-Venezuela : alliés face aux ingérences américaines ?  L'Iran a proposé son aide au Venezuela dans le bras de fer qui l'oppose aux États-Unis, dénonçant les sanctions américaines et affirmant sa solidarité avec Caracas.  Pourquoi Téhéran propose-t-il son soutien à Caracas ? Quelle forme pourrait prendre cette coopération ? Avec Pascal Drouhaud, président de l'association LatFran, spécialiste de l'Amérique latine.

durée : 00:39:02 - Questions du soir : le débat - par : Antoine Dhulster, Louise Cognard - Le 18 décembre dernier, Ursula Von der Leyen a annoncé reporter d'un mois la signature de l'accord de libre-échange avec le Mercosur. Sur fond de désaccords autour de l'agriculture, les tergiversations européennes ne risquent-elles pas de profiter à la Chine, autre partenaire de choix du Mercosur ? - réalisation : Margot Page - invités : Mathilde Dupré Économiste, co-directrice de l'Institut Veblen; Alain Guillemoles Journaliste en charge de l'Union européenne à La Croix; Jean-Luc Demarty Ancien directeur général du Commerce et de l'Agriculture à la Commission européenne

The FTC may be quietly reviving its controversial Click-to-Cancel rule — and companies with subscription or auto-renewal programs should take notice. After the Eighth Circuit vacated the original rule on procedural grounds, consumer groups petitioned the FTC to reopen the rulemaking, and the Commission has now invited public comment, signaling that federal scrutiny of cancellation practices is far from over. For legal, compliance, and marketing teams, this development underscores the ongoing risk around negative-option offers and the need to evaluate enrollment disclosures and cancellation flows now, not later. Hosted by Simone Roach. Based on a blog post by Gonzalo E. Mon, Donnelly L. McDowell, and Aaron J. Burstein.

A few years ago, John Haffner was digging in his White River Junction backyard when his shovel hit a glass bottle buried underground. Then he found another, and another — all with words like “remedy,” “tonic” and “quick cure” embossed on them. John wants to know why there are so many of these old bottles around and, more importantly, what was in them? Local historian and independent reporter Kelby Greene is on the case, unraveling the snake oil sensation that swept the Green Mountain State. You can find the web version of this story here.Reporting for this story was supported by a grant from Vermont Humanities, in partnership with the Vermont 250 Commission and JAM, Junction Arts and Media. For more, check out the podcast series Roadside Vermont.This episode was reported by Kelby Greene and produced by Josh Crane. Editing and additional production from the rest of the BLS team: Sabine Poux and Burgess Brown. Our executive producer is Angela Evancie. Theme music by Ty Gibbons; other music by Blue Dot Sessions.Special thanks to Catherine Hurley, Shirley Duso and Creighton Hall.As always, our journalism is better when you're a part of it: Ask a question about Vermont Sign up for the BLS newsletter Say hi on Instagram and Reddit @bravestatevt Drop us an email: hello@bravelittlestate.org Make a gift to support people-powered journalism Tell your friends about the show! Brave Little State is a production of Vermont Public and a proud member of the NPR Network.

   President Trump has announced the United States has surrounded Venezuela with a complete blockade of sanctioned oil tankers in an effort to cut off all the money flowing into that country.  At the same time, he's announced he will address the nation Wednesday night from the White House in a speech that's expected to feature accomplishments and plans for 2026.  Let's hope he stays on script.    Marco Rubio makes a bold statement about what will keep him from running for president in 2028.      The Royals seem to be infuriating everyone except the people that make the decision on whether they can build a ballpark at 119th and Nall.  The City of Lenexa is trying to pull another crazy liberal scam on its good citizens after failing with a homeless shelter.  Wait until you hear this joke.    There's a ton of reporting on Travis Kelce's future and we'll explain why you shouldn't be listening to any of it just yet.  Darryn Peterson sits for the 8th time in 12 games as KU gets an easy win.   Kansas State is losing its only good wide receiver to the transfer portal and our Final Final is not great news for KC.